Esperion Therapeutics, Inc.
ESPRNASDAQHealthcare● Active
$3.15
+$0.02(+0.64%)
Market Cap$654912465
P/E Ratio—
52W High$4.18
52W Low$0.95
Esperion Therapeutics, Inc. (ESPR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ESPR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.40B | $0.33B | $0.12B | $0.08B | $0.08B |
| Cost of Revenue | $0.13B | $0.07B | $0.04B | $0.03B | $0.01B |
| Gross Profit | $0.27B | $0.26B | $0.07B | $0.05B | $0.06B |
| Gross Margin %(computed) | 67.95% | 79.36% | 62.81% | 64.27% | 81.88% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.05B | $0.09B | $0.12B | $0.11B |
| G&A Expenses | $0.00B | $0.14B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.21B | $0.21B | $0.23B | $0.23B | $0.29B |
| Operating Income | $0.06B | $0.05B | ($0.16B) | ($0.18B) | ($0.23B) |
| Operating Margin %(computed) | 14.95% | 16.37% | -133.72% | -237.83% | -289.02% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.08B | $0.06B | $0.06B | $0.06B | $0.05B |
| Income Before Tax | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Net Margin %(computed) | -5.63% | -15.57% | -179.87% | -309.58% | -343.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.11 | $-0.28 | $-2.03 | $-4.33 | $-11.03 |
| Wtd Avg Shares | 0.21B | 0.19B | 0.10B | 0.07B | 0.03B |
| EBITDA | $0.06B | $0.01B | ($0.15B) | ($0.18B) | ($0.22B) |
| EBITDA Margin %(computed) | 14.95% | 2.28% | -129.03% | -233.65% | -283.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Esperion Therapeutics, Inc. data
About Esperion Therapeutics, Inc. (ESPR) Income Statement
Esperion Therapeutics, Inc. (ESPR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ESPR reported revenue of $0.40B, gross profit of $0.27B (gross margin 67.95%), and net income of ($0.02B) — a net profit margin of -5.63%.
Frequently asked questions
ESPR · 4 questionsEsperion Therapeutics, Inc. (ESPR) reported revenue of $0.40B for 2025, up 21.3% year-over-year.
ESPR revenueESPR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08